WIXOM, MI–(Marketwired – May 20, 2013) – Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today the closing of the sale of 13,196,721 common shares, including 1,721,311 shares of common to cover overallotments, at $3.05 per share in an underwritten public offering for an aggregate offering amount of approximately $40.3 million. The net proceeds from the offering, after commissions and other estimated offering expenses, were approximately $37.7 million. Rockwell Medical plans to use the net proceeds to fund SFP clinical trials and for other general corporate purposes.
Chardan Capital Markets, LLC acted as the sole book-running manager for the offering. Summer Street Research Partners acted as lead manager for the offering. C&Co/PrinceRidge LLC acted as co-manager for the offering.
